Cardiovascular risk with long-term use of proton pump inhibitors: myth or reality. A review
- Authors: Trukhan D.I.1, Filimonov S.N.2,3
-
Affiliations:
- Omsk State Medical University
- Research Institute for Complex Problems of Hygiene and Occupational Diseases
- Novokuznetsk State Institute for Further Training of Physicians – Branch Campus of the Russian Medical Academy of Continuous Professional Education
- Issue: Vol 26, No 1 (2024): Cardiology and Nephrology
- Pages: 55-60
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/256827
- DOI: https://doi.org/10.26442/20751753.2024.1.202532
- ID: 256827
Cite item
Full Text
Abstract
Proton pump inhibitors (PPIs) are the most effective drugs for treating acid-related diseases. In recent decades, the use of PPIs has increased exponentially. From gastroenterological practice, PPIs are being actively introduced into other specialties, in particular in cardiology and rheumatology, where they are used to protect the mucous membrane of the gastrointestinal tract and prevent gastrointestinal bleeding during long-term antithrombotic therapy and long-term use of non-steroidal anti-inflammatory drugs. For a long time, PPIs were considered completely safe drugs for both short-term and long-term use. However, modern clinical guidelines note that when prescribing PPIs in large doses for a long period, the possibility of side effects should be taken into account. In recent years, a number of foreign reviews have been published that examine the relationship between PPIs and a number of diseases/conditions, including the question of a possible association of PPI use with an increased risk of cardiovascular complications, but note the inconsistency of these data. We searched the PubMed and Scopus information databases for publications on the safety of PPI use, including sources up to 12/01/2023. In this review, we examined the possible cardiovascular risk of long-term use of PPIs. Analysis of publications, despite a number of contradictions, allows us to conclude that the cardiovascular risk with long-term use of PPIs is real and must be taken into account when prescribing PPIs for a long period and to comorbid/multimorbid patients.
Full Text
##article.viewOnOriginalSite##About the authors
Dmitry I. Trukhan
Omsk State Medical University
Author for correspondence.
Email: dmitry_trukhan@mail.ru
ORCID iD: 0000-0002-1597-1876
D. Sci. (Med.), Assoc. Prof.
Russian Federation, OmskSergej N. Filimonov
Research Institute for Complex Problems of Hygiene and Occupational Diseases; Novokuznetsk State Institute for Further Training of Physicians – Branch Campus of the Russian Medical Academy of Continuous Professional Education
Email: fsn42@mail.ru
ORCID iD: 0000-0001-6816-6064
D. Sci. (Med.), Prof., Novokuznetsk State Institute for Further Training of Physicians – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Research Institute for Complex Problems of Hygiene and Occupational Diseases
Russian Federation, Novokuznetsk; NovokuznetskReferences
- Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике. Российский кардиологический журнал. 2022;27(7):5155 [2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Russian Journal of Cardiology. 2022;27(7):5155 (in Russian)]. doi: 10.15829/1560-4071-2022-5155
- Трухан Д.И., Давыдов Е.Л., Шевченко Г.Ю. Контроль гликемии у коморбидных пациентов – важный компонент в профилактике прогрессирования сердечно-сосудистых заболеваний. Медицинский Совет. 2023;17(16):60-7 [Trukhan DI, Davidov EL, Shevchenko GYu. Glycaemic control in comorbid patients: an important element of CVD progression prevention. Meditsinskiy Sovet. 2023;17(16):60-7 (in Russian)]. doi: 10.21518/ms2023-307
- Число умерших по причинам смерти в 2021 году. Росстат. Режим доступа: https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Frosstat.gov.ru%2Fstorage%2Fmediabank%2Fdemo24-2_2021.xlsx&wdOrigin=BROWSELINK. Ссылка активна на 12.12.2023 [Chislo umershikh po prichinam smerti v 2021 godu. Rosstat. Available at: https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Frosstat.gov.ru%2Fstorage%2Fmediabank%2Fdemo24-2_2021.xlsx&wdOrigin=BROWSELINK. Accessed: 12.12.2023 (in Russian)].
- Тарасова Л.В., Трухан Д.И. Лекарственная безопасность в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2013;4:81-7 [Tarasova LV, Trukhan DI. Drug safety in gastroenterology. Experimental and Clinical Gastroenterology. 2013;4:81-7 (in Russian)].
- Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности. Клинический разбор в общей медицине. 2020;2:29-39 [Trukhan DI. Rational pharmacotherapy in real clinical practice through the prism of multimorbidity and drug safety. Clinical Review for General Practice. 2020;2:29-39 (in Russian)]. doi: 10.47407/kr2020.1.2.00015
- Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности. Справочник поликлинического врача. 2019;2:10-8 [Trukhan DI, Konshu NV. Rational pharmacotherapy in the clinic of internal diseases through the prism of multimorbidity and drug safety. Handbook for Practitioners Doctors. 2019;2:10-8 (in Russian)].
- Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97 (in Russian)]. doi: 10.22416/1382-4376-2020-30-4-70-97
- Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis. 2020;75(4):497-507. doi: 10.1053/j.ajkd.2019.07.012
- Novotny M, Klimova B, Valis M. PPI Long Term Use: Risk of Neurological Adverse Events? Front Neurol. 2019;9:1142. doi: 10.3389/fneur.2018.01142
- Salvo EM, Ferko NC, Cash SB, et al. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther. 2021;54(2):129-43. doi: 10.1111/apt.16407
- Chinzon D, Domingues G, Tosetto N, Perrotti M. Safety of long-term proton pump inhibitors: facts and myths. Arq Gastroenterol. 2022;59(2):219-25. doi: 10.1590/S0004-2803.202202000-40
- Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023;59(2):115-27. doi: 10.4068/cmj.2023.59.2.115
- Smith CA, Ebrahimpour A, Novikova L, et al. Esomeprazole covalently interacts with the cardiovascular enzyme dimethylarginine dimethylaminohydrolase: Insights into the cardiovascular risk of proton pump inhibitors. Biochim Biophys Acta Gen Subj. 2022;1866(8):130149. doi: 10.1016/j.bbagen.2022.130149
- Ariel H, Cooke JP. Cardiovascular risk of proton pump inhibitors. Methodist Debakey Cardiovasc J. 2019;15(3):214-9. doi: 10.14797/mdcj-15-3-214
- Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021;76(1):13-21. doi: 10.1016/j.therap.2020.06.019
- Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331-42. doi: 10.1093/ndt/gfw470
- Rooney MR, Bell EJ, Alonso A, et al. Proton Pump Inhibitor Use, Hypomagnesemia and Risk of Cardiovascular Diseases: The Atherosclerosis Risk in Communities (ARIC) Study. J Clin Gastroenterol. 2021;55(8):677-83. doi: 10.1097/MCG.0000000000001420
- Sun S, Cui Z, Zhou M, et al. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastroesophageal reflux disease: a meta-analysis. Neurogastroenterol Motil. 2017;29(2):e12926. doi: 10.1111/nmo.12926
- Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012–2016). BMC Cardiovasc Disord. 2017;17(1):3. doi: 10.1186/s12872-016-0453-6
- Pang J, Wu Q, Zhang Z, et al. Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2019;23:100317. doi: 10.1016/j.ijcha.2018.12.016
- Freedberg DE, Yang YX, Abrams JA. Proton pump inhibitors and myocardial infarction. Gastroenterology. 2015;149(4):830-3. doi: 10.1053/j.gastro.2015.08.002
- Tseng HJ, Cheng CM, Tsai SJ, et al. Proton pump inhibitor exposure and acute myocardial infarction risk: a nested cohort study. Cardiovasc Toxicol. 2021;21(6):444-50. doi: 10.1007/s12012-021-09637-2
- Qian Y, Jick S. Proton-pump inhibitor use and myocardial infarction: a nested case-control study in the UK Clinical Practice Research Datalink. Epidemiology. 2020;31(3):423-31. doi: 10.1097/EDE.0000000000001152
- Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845-53. doi: 10.1161/CIRCULATIONAHA.113.003602
- Kang MK, Shin JH, Kim TJ, et al. Use of proton pump inhibitor may be associated with progression of cerebral small vessel disease. PLoS One. 2022;17(12):e0279257. doi: 10.1371/journal.pone.0279257
- Sehested TSG, Gerds TA, Fosbøl EL, et al. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2018;283(3):268-81. doi: 10.1111/joim.12698
- Wang YF, Chen YT, Luo JC, et al. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol. 2017;112(7):1084-93. doi: 10.1038/ajg.2017.101
- Yang M, He Q, Gao F, et al. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Med. 2021;19(1):316. doi: 10.1186/s12916-021-02180-5
- Li S, Liu F, Chen C, et al. Real-world relationship between proton pump inhibitors and cerebro-cardiovascular outcomes independent of clopidogrel. Int Heart J. 2019;60(4):910-8. doi: 10.1536/ihj.18-584
- Farhat N, Fortin Y, Haddad N, et al. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. Crit Rev Toxicol. 2019;49(3):215-61. doi: 10.1080/10408444.2019.1583167
- Nolde M, Ahn N, Dreischulte T, et al. The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008–2018). Aliment Pharmacol Ther. 2021;54(8):1033-40. doi: 10.1111/apt.16565
- Shang YS, Zhong PY, Ma Y, et al. Efficacy and safety of proton pump inhibitors in patients with coronary artery diseases receiving oral antiplatelet agents and/or anticoagulants: A systematic review and meta-analysis. J Cardiovasc Pharmacol. 2022;80(1):1-12. doi: 10.1097/FJC.0000000000001284
- Nolde M, Ahn N, Dreischulte T, et al. Proton pump inhibitors and the risk of cardiovascular events and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2022;106:80-9. doi: 10.1016/j.ejim.2022.09.021
- Chui CSL, Cheung KS, Brown JP, et al. Proton pump inhibitors and myocardial infarction: an application of active comparators in a self-controlled case series. Int J Epidemiol. 2023;52(3):899-907. doi: 10.1093/ije/dyac196
- Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2021;70(6):1070-7. doi: 10.1136/gutjnl-2020-322557
- Czarniak P, Ahmadizar F, Hughes J, et al. Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study. Br J Clin Pharmacol. 2022;88(6):2718-26. doi: 10.1111/bcp.15182
- Ciardullo S, Rea F, Savaré L, et al. Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study. J Clin Endocrinol Metab. 2022;107(7):e2671-9. doi: 10.1210/clinem/dgac231
- Guo YR, Liu XM, Wang GX. Exposure to proton pump inhibitors and risk of diabetes: A systematic review and meta-analysis. World J Diabetes. 2023;14(2):120-9. doi: 10.4239/wjd.v14.i2.120
- Schiffl H, Al-Nemnem E, Lang SM. Proton-pump inhibitors and chronic kidney disease: hidden consequences of an inappropriate drug use? Saudi J Kidney Dis Transpl. 2020;31(2):312-9. doi: 10.4103/1319-2442.284005
- Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17(1):112. doi: 10.1186/s12882-016-0325-4
- Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193
- Xie Y, Bowe B, Li T, et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482-94. doi: 10.1016/j.kint.2016.12.021
- Yang H, Juang SY, Liao KF. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res Clin Pract. 2019;147:67-75. doi: 10.1016/j.diabres.2018.11.019
- Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study. Pharmacotherapy. 2019;39(4):443-53. doi: 10.1002/phar.2235
- Rodríguez-Poncelas A, Barceló MA, Saez M, Coll-de-Tuero G. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS One. 2018;13(10):e0204231. doi: 10.1371/journal.pone.0204231
- Guedes JVM, Aquino JA, Castro TLB, et al. Omeprazole use and risk of chronic kidney disease evolution. PLoS One. 2020;15(3):e0229344. doi: 10.1371/journal.pone.0229344
- Zhang XY, He QS, Jing Z, et al. Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank. Front Pharmacol. 2022;13:949699. doi: 10.3389/fphar.2022.949699
- Wu CC, Liao MH, Kung WM, Wang YC. Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies. J Clin Med. 2023;12(6):2262. doi: 10.3390/jcm12062262
- Nozaki M, Suzuki T, Hirano M. Rhabdomyolysis associated with omeprazole. J Gastroenterol. 2004;39(1):86. doi: 10.1007/s00535-003-1231-7
- Bebarta VS, King JA, McDonough M. Proton pump inhibitor-induced rhabdomyolysis and hyponatremic delirium. Am J Emerg Med. 2008;26(4):519.e1-2. doi: 10.1016/j.ajem.2007.08.026
- Tanaka K, Nakada TA, Abe R, et al. Omeprazole-associated rhabdomyolysis. Crit Care. 2014;18(4):462. doi: 10.1186/s13054-014-0462-8
- Tröger U, Reiche I, Jepsen MS, et al. Esomeprazole-induced rhabdomyolysis in a patient with heart failure. Intensive Care Med. 2010;36(7):1278-9. doi: 10.1007/s00134-010-1854-0
- Jeon DH, Kim Y, Kim MJ, et al. Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report. Medicine (Baltimore). 2016;95(29):e4313. doi: 10.1097/MD.0000000000004313
- Nishikawa J, Hosokawa A, Fuchino M, et al. Rhabdomyolysis associated with long-term treatment of esomeprazole. Nihon Shokakibyo Gakkai Zasshi. 2018;115(3):299-304 [Article in Japanese]. doi: 10.11405/nisshoshi.115.299
- Ertekin YH, Yakar B, Ertekin H, et al. Diclofenac- and Pantoprazole-Induced Rhabdomyolysis: A Potential Drug Interaction. Drug Saf Case Rep. 2015;2(1):10. doi: 10.1007/s40800-015-0012-6
- Bourlon S, Veyrac G, Armand C, et al. Rhabdomyolysis during treatment with rabeprazole (Pariel), a proton pump inhibitor combined with domperidone (Peridys). Therapie. 2002;57(6):597-600 [Article in French].
- Sun Y, Zhang A, Zuo M, et al. A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database. J Gastroenterol Hepatol. 2023. doi: 10.1111/jgh.16411
- Montastruc JL. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins. Br J Clin Pharmacol. 2023;89(8):2636-8. doi: 10.1111/bcp.15757
- Mitsuboshi S, Hamano H, Kuniki Y, et al. Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional Databases. Ann Pharmacother. 2023;57(11):1255-63. doi: 10.1177/10600280231156270
- Altebainawi AF, Alfaraj LA, Alharbi AA, et al. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) data-base. Ther Adv Drug Saf. 2023;14:20420986231154075. doi: 10.1177/20420986231154075
- Duncan SJ, Howden CW. Proton Pump Inhibitors and Risk of Rhabdomyolysis. Drug Saf. 2017;40(1):61-4. doi: 10.1007/s40264-016-0473-2
- Haastrup PF, Jarbøl DE, Thompson W, et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol. 2021;8(1):e000563. doi: 10.1136/bmjgast-2020-000563
- Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-15. doi: 10.1053/j.gastro.2017.01.031
- Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162(4):1334-42. doi: 10.1053/j.gastro.2021.12.247
- Воробьева Н.М., Ткачева О.Н. Безопасность антитромботической терапии в кардиологической практике: как защитить слизистую желудочно-кишечного тракта? Терапия. 2022;4:134-40 [Vorobyeva NM, Tkacheva ON. Safety of antithrombotic therapy in cardiological practice: how to protect tunica mucosa of gastrointestinal tract? Therapy. 2022;4:134-40 (in Russian)]. doi: 10.18565/therapy.2022.4.134-140
- Zhou M, Zhang J, Liu J, et al; CCC-ACS Investigators. Proton Pump Inhibitors and In-Hospital Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy. Mayo Clin Proc. 2022;97(4):682-92. doi: 10.1016/j.mayocp.2021.11.037
- Ткачева О.Н., Воробьева Н.М., Котовская Ю.В., и др. Антитромботическая терапия в пожилом и старческом возрасте: согласованное мнение экспертов Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии. Кардиоваскулярная терапия и профилактика. 2021;20(3):2847 [Tkacheva ON, Vorobyeva NM, Kotovskaya YuV, et al. Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. Cardiovascular Therapy and Prevention. 2021;20(3):2847 (in Russian)]. doi: 10.15829/1728-8800-2021-2847
- Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты. Терапия. 2021;7(10):23-41 [Experts consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Therapy. 2021;7(10):23-41 (in Russian)]. doi: 10.18565/therapy.2021.10.23–41